Major China stock selloff likely a 'localized' issue that won't get in way of U.S. earnings
 
A major selloff of Chinese stocks stemming from Beijing's regulatory crackdown on private businesses in a variety of sectors, including technology and education, is likely a "localized" phenonemon, John Bilton, the head of global multi-asset strategy at J.P. Morgan Asset Management, told Bloomberg TV on Tuesday.
Bilton said fears may spread to the United States and Europe, where "investors who perhaps have got a little bit more ... nervousness to them may want to ... sit on their hands." But, he continued, "let's make no mistake: What you're seeing going on right now is a classic battle between earnings delivery, which is coming through strongly out of the U.S., strongly out of Europe, and then you're seeing a reminder of some of the regulatory issues that persist within China."
All told, what's happening in China is causing some investors "around the globe to question their exposures, but by and large, it's not getting in the way of what's been an absolutely thumping earnings season coming out of U.S. stocks, and also out of Europe."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
 
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
- 
 Testosterone therapy in women highlights the lack of women’s health research Testosterone therapy in women highlights the lack of women’s health researchThe explainer There is no FDA-approved testosterone product for women 
- 
 Magazine solutions - November 7, 2025 Magazine solutions - November 7, 2025Puzzles and Quizzes Issue - November 7, 2025 
- 
 Magazine printables - November 7, 2025 Magazine printables - November 7, 2025Puzzles and Quizzes Issue - November 7, 2025 
- 
 Will latest Russian sanctions finally break Putin’s resolve? Will latest Russian sanctions finally break Putin’s resolve?Today's Big Question New restrictions have been described as a ‘punch to the gut of Moscow’s war economy’ 
- 
 Warner Bros. explores sale amid Paramount bids Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties 
- 
 China’s rare earth controls China’s rare earth controlsThe Explainer Beijing has shocked Washington with export restrictions on minerals used in most electronics 
- 
 Is a financial market crash around the corner? Is a financial market crash around the corner?Talking Points Observers see echoes of 1929 
- 
 Gold tops $4K per ounce, signaling financial unease Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war 
- 
 The struggles of Aston Martin: burning cash not rubber The struggles of Aston Martin: burning cash not rubberIn the Spotlight The car manufacturer, famous for its association with the James Bond franchise, is ‘running out of road’ 
- 
 Electronic Arts to go private in record $55B deal Electronic Arts to go private in record $55B dealspeed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’ 
- 
 The AI bubble and a potential stock market crash The AI bubble and a potential stock market crashToday's Big Question Valuations of some AI start-ups are 'insane', says OpenAI CEO Sam Altman 
